Morohuntodun O. Oni1,2*, Alexandria Hawkins, BS2,3*, Emily Stein2,4*, Steven G. Dubois, MD, MS2,3,5*, Katie A. Greenzang, MD, EdM2,3,5,6*, Rahela Aziz-Bose, MD2,3,5,6, Christine Duncan, MD2,3,5, Allison F. O'Neill, MD2,3,5*, Andrew E. Place, MD, PhD2,3,5, Puja J. Umaretiya, MD2,3,5,6*, Natasha Archer, MD2,5,7 and Kira Bona, MD, MPH2,3,5,6
1Dana-Farber / Boston Children’s Cancer and Blood Disorders Center, Brookline, MA
2Division of Pediatric Hematology/Oncology, Boston Children’s Hospital, Boston, MA
3Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
4Dana-Farber / Boston Children’s Cancer and Blood Disorders Center, Boston, MA
5Department of Pediatrics, Harvard Medical School, Boston, MA
6Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA
7Dana-Farber/Boston Children's Cancer and Blood Disorder Ctr., Boston, MA